This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
J&J Signs Another Collaboration to Develop Coronavirus Vaccine
by Zacks Equity Research
J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates
by Kinjel Shah
Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.
Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Geron (GERN) reports encouraging fourth-quarter 2019 results. Operating expenses increase on a year-over-year basis.
Emergent (EBS) Begins Development of Treatments for COVID-19
by Zacks Equity Research
Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
Mallinckrodt Up on New York's Support for Opioid Settlement
by Zacks Equity Research
Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.
Emergent BioSolutions Collaborates for Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.
AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure
by Zacks Equity Research
AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment
The Zacks Analyst Blog Highlights: Microsoft, Alphabet, Johnson & Johnson, Morgan Stanley and Bank of America
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Alphabet, Johnson & Johnson, Morgan Stanley and Bank of America
Millennials Are Inclined Toward ESG: Here's Why
by Zacks Equity Research
ESG investment has carved a niche in stock markets and millennials are the ones driving its rapid growth.
Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
by Kinjel Shah
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
Johnson & Johnson (JNJ) Stock Moves -1.02%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $142.01, moving -1.02% from the previous trading session.
J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
by Zacks Equity Research
Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work
by Kinjel Shah
President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
by Kinjel Shah
Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.
AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.
Top Stock Reports for Eli Lilly, Union Pacific & Lockheed
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Union Pacific (UNP) and Lockheed Martin (LMT).
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4
by Zacks Equity Research
Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $143.68, marking a -0.67% move from the previous day.